The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Mounjaro is approved as an adjunct to a reduced-calorie diet and increased physical activity for adults with an initial body ...

US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

US pharmaceutical giant Eli Lilly has launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India following ...

Objective Sodium–glucose cotransporter 2 (SGLT-2) inhibitors are the most recently approved antihyperglycemic medications. We sought to describe their association with euglycemic diabetic ...

AstraZeneca has revealed plans to set up a new strategic R&D hub in Cambridge, Massachusetts as it reported a massive increase in first-quarter revenues, driven by COVID-19 and oncology drugs and ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

这项荟萃分析旨在比较 iGlarLixi 与甘精胰岛素（insulin glargine）治疗 2 型糖尿病（T2D）的疗效和安全性。研究人员系统检索了 PubMed、考克兰图书馆（the Cochrane Library）和 EMBASE 数据库，以找出比较 iGlarLixi 和甘精胰岛素在 2 型糖尿病患者中应用的随机对照试验（RCTs）。

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...